文献速递甲状腺核医学核素与放射性配体治疗

甲状腺激素水平升高与癌症的关系

Higher thyroid hormone levels and cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-09-18

本叙述性综述通过检索Google Scholar和PubMed 2000至2020年英文文献,总结甲状腺功能亢进、甲状腺激素正常高值水平与癌症风险及预后的关系,并讨论癌症患者甲亢的临床管理及核医学作用。多数证据提示临床和亚临床甲亢与多种癌症风险及较差预后相关,强调快速恢复甲状腺功能正常及放射性碘治疗的重要性。

要点

  • 临床和亚临床甲亢与多种癌症发生风险及较差预后相关。
  • 三碘甲状腺原氨酸和甲状腺素在体外、体内及人群研究中显示促癌作用。
  • 多数癌症患者甲亢治疗首选放射性碘,以快速恢复甲状腺功能正常。

核心结论

  • 绝大多数证据提示临床和亚临床甲亢与多种类型癌症发生风险相关,且甲亢与较差的癌症预后相关。
  • 快速恢复甲状腺功能正常至关重要,放射性碘治疗是大多数癌症患者甲亢的首选治疗。

研究设计与样本

  • 叙述性综述,由独立审稿人通过Google Scholar和PubMed电子数据库全面检索。
  • 检索限于2000至2020年发表的英文手稿。

主要发现

  • 大量体外、体内和人群研究表明三碘甲状腺原氨酸和甲状腺素具有促癌作用。
  • 甲状腺激素被视为肿瘤生长、增殖和进展的介质。
  • 许多人群和病例对照研究提示甲亢及甲状腺激素正常高值水平与多种实体瘤及血液系统恶性肿瘤风险增加相关,但结果并非完全一致。

临床怎么用

  • 癌症患者甲亢管理中应强调快速恢复甲状腺功能正常。
  • 大多数癌症患者甲亢治疗首选放射性碘治疗,以实现永久性解决并可能降低甲亢对新发癌症及现有癌症病程的不良影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This narrative review aims to summarize the relationship between hyperthyroidism, upper reference range thyroid hormone (TH) levels, and cancer, and to address the clinical management of hyperthyroidism in cancer patients. METHODS: A comprehensive search was performed by an independent reviewer through Google Scholar and PubMed Electronic databases. All searches were restricted to English language manuscripts published between 2000 and 2020. RESULTS: Numerous in vitro, in vivo, and population-based studies suggest cancer-stimulating effect of triiodothyronine and thyroxin. THs are presented as mediators for tumor growth, proliferation, and progression. Many population and case-control studies suggest an increased risk of several solid but also hematologic malignancies in relation to hyperthyroidism and upper normal range TH levels. However, results are not unambiguous. In this review, we will summarize population and case-control studies that investigated the relationship between hyperthyroidism, upper reference range TH levels, lower thyrotropin (TSH) levels, lower reference range TSH levels with cancer risk, cancer prognosis, and cancer outcome. The vast majority of evidence suggests an association between clinical and subclinical hyperthyroidism with the risk of developing several types of cancer. Furthermore, hyperthyroidism is also linked with a poorer cancer prognosis. In this review, we will also discuss the diagnosis of hyperthyroidism in patients with pre-existing cancer and cover the management of hyperthyroidism in cancer patients, with special attention on the role of nuclear medicine. CONCLUSIONS: It is crucial to emphasize the importance of the rapid establishment of euthyroidism, and consequently, the importance of radioiodine therapy, as the therapy of choice in most cancer patients. We want to show that in this day and age there still is a high relevance for I-131 to achieve a permanent solution and thus likely reduce the risk of adverse influence of hyperthyroidism on the occurrence of new and course of existing cancer cases.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Petranović Ovčariček P, Verburg FA, Hoffmann M, et al. Higher thyroid hormone levels and cancer. Eur J Nucl Med Mol Imaging. 2020. PMID: 32944783. doi:10.1007/s00259-020-05018-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。